Description
ERLONAT – Erlotinib 100 mg and 150 mg. is supplied for Tenders, Emergency imports, Orphan drug, Reference listed drugs, Comparator Drug, and Name patient medicine.
General Warning
Patients with this medication may experience mild rashes as well as infections. Immediately seek help from your medical team to receive proper treatment.
What is ERLONAT ?
ERLONAT is indicated for :
- Maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.
- Treatment of locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
- First-line treatment of patients with locally advanced or metastatic pancreatic cancer, in combined with gemcitabine.
Uses Of Erlotinib
Erlonat (Erlotinib) is specifically indicated for the treatment of Non-Small Cell Lung Cancer (NSCLC). Also, Erlotinib the FDA approved medication for use in a patient with Pancreatic Cancer.
Dosage
Take this medication as your health care provider has instructed. It would be best if you swallowed an entire tablet at the same time each day for better outcomes. Never try to take any dose in additional quantities. Do not start or stop a specific dose by yourself until you get words from your doctor.
How does an Erlonat Tablet Work?
Erlonat is an Epidermal Growth Factor Receptor Inhibitor. It works by targeting and binding the Epidermal Growth Factor Receptor Tyrosine Kinase, which is rarely mutated in numerous forms of specific cancer. Reversibly, it binds ATP (Adenosine Triphosphate). Erlonat mainly works by blocking and resisting the abnormal protein that signals in developing the cancer cells. In 2004, this medication was approved by the FDA for medical use in the United States.